Decipher test may guide intensified prostate cancer therapy
Researchers analyzed Decipher molecular test scores from real-world data and the STAMPEDE trial to see whether the test could identify men with high-risk localized prostate cancer likely to benefit from adding abiraterone. Higher scores were linked to greater risks of distant metastasis and prostate cancer death. The findings suggest the test may help tailor treatment intensity.
Prostate cancer is the most common male cancer, with over one million cases worldwide in 2013. Its course varies widely, so clinicians must weigh extra treatment against side effects and reduced quality of life.
In STAMPEDE, adding abiraterone to standard care for high-risk localized disease cut death risk by half and slowed progression. Researchers tested whether Decipher, a tissue-based molecular assay, could identify likely beneficiaries. Across real-world and trial data, higher scores tracked greater metastasis and prostate-cancer mortality risk.
If validated, Decipher-guided decisions could affect men with high-risk localized prostate cancer by helping some avoid unnecessary intensified therapy and its side effects, while directing abiraterone toward those most likely to benefit. This may reduce overtreatment and improve quality of life, but could also raise questions about test access, cost, and equitable use across health systems. Clinicians and patients would need clear evidence before routine adoption.